The future of ALL treatment: moving away from stem cell transplantation

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into future treatment approaches in acute lymphoblastic leukemia (ALL), highlighting the growing role of inotuzumab ozogamicin, blinatumomab, and CAR-T cells. Dr Short further explains the importance of moving away from stem cell transplantation and bringing novel agents and CAR-T therapy into the frontline setting, and highlights approaches for patients with relapsed/refractory (R/R) disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.